Find Paid Clinical Trials in North Dakota

Paid Clinical Trials and Focus Groups

Find Paid Clinical Trials

Paid Clinical Trials in North Dakota

Top of Directory » All Locations » United States » North Dakota




  • BIBF 1120 or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

    Conditions:   Ovarian Neoplasms;   Peritoneal Neoplasms
    Interventions:   Drug: BIBF 1120;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim Pharmaceuticals
    Not yet recruiting - verified November 2009

  • Study Evaluating the Efficacy and Safety of SBI-087 in Seropositive Subjects With Active Rheumatoid Arthritis

    Condition:   Active Rheumatoid Arthritis
    Intervention:   Drug: SBI-087
    Sponsor:   Wyeth
    Recruiting - verified November 2009

  • Study of Tissue and Blood Samples From Patients With Low-Grade Glioma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Genetic: fluorescence in situ hybridization;   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunohistochemistry staining method
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Tissue and Blood Samples From Patients With High-Grade Glioma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Genetic: DNA ploidy analysis;   Genetic: fluorescence in situ hybridization;   Genetic: microsatellite instability analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunohistochemistry staining method
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Preliminary Comparison of the Blood Levels of Medications in Obese Subjects Compared to Post-Gastric Bypass Subjects

    Condition:   Gastric Bypass
    Intervention:   Drug: Sertraline
    Sponsors:   Neuropsychiatric Research Institute, Fargo, North Dakota;   University of North Dakota
    Recruiting - verified November 2009

  • Carboplatin and Paclitaxel Combined With Cetuximab and/or Cixutumumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: cetuximab;   Biological: cixutumumab;   Drug: carboplatin;   Drug: paclitaxel
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • The Dual Antiplatelet Therapy Study (DAPT Study)

    Condition:   Coronary Artery Disease
    Interventions:   Drug: Placebo & Aspirin;   Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
    Sponsors:   Harvard Clinical Research Institute;   Abbott;   Boston Scientific Corporation;   Bristol-Myers Squibb;   Sanofi-Synthelabo;   Cordis Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.;   Medtronic
    Recruiting - verified November 2009

  • A Study in Patients With Rheumatoid Arthritis

    Condition:   Rheumatoid Arthritis
    Interventions:   Biological: LY2439821;   Drug: Placebo
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy

    Conditions:   Breast Cancer;   Hot Flashes;   Menopausal Symptoms;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Dietary Supplement: flaxseed;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine Carcinosarcoma

    Condition:   Sarcoma
    Interventions:   Drug: carboplatin;   Drug: ifosfamide;   Drug: paclitaxel
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

    Condition:   Myelofibrosis
    Interventions:   Drug: INCB018424;   Drug: Placebo
    Sponsor:   Incyte Corporation
    Recruiting - verified November 2009

  • Study of Patients With Advanced Non-Small Cell Lung Cancer

    Condition:   Advanced Non-Small Cell Lung Cancer
    Interventions:   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Bevacizumab
    Sponsor:   Eli Lilly and Company
    Recruiting - verified November 2009

  • Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Clinical Evaluation of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) NX02-0018

    Condition:   Benign Prostatic Hyperplasia (BPH)
    Interventions:   Drug: NX-1207;   Drug: Placebo
    Sponsor:   Nymox Corporation
    Recruiting - verified October 2009

  • Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

    Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
    Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease

    Condition:   Alzheimer's Disease
    Intervention:   Drug: Dimebon
    Sponsors:   Pfizer;   Medivation, Inc.
    Recruiting - verified November 2009

  • A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates

    Condition:   Postmenopausal Osteoporosis
    Interventions:   Drug: Ibandronate;   Drug: Denosumab
    Sponsor:   Amgen
    Not yet recruiting - verified November 2009

  • Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
    Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary

    Condition:   Carcinoma of Unknown Primary
    Interventions:   Drug: carboplatin;   Drug: everolimus;   Drug: paclitaxel;   Genetic: gene expression analysis;   Other: laboratory biomarker analysis
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Samples From Patients With Lung Cancer

    Condition:   Lung Cancer
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

    Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
    Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

    Condition:   Brain and Central Nervous System Tumors
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer

    Condition:   Chemotherapy Induced Anemia
    Interventions:   Biological: Biological: ACE-011;   Drug: Placebo
    Sponsor:   Acceleron Pharma, Inc.
    Recruiting - verified October 2009

  • Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

    Condition:   Neuroblastoma
    Interventions:   Genetic: loss of heterozygosity analysis;   Other: cytology specimen collection procedure;   Procedure: biopsy
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

    Conditions:   Anal Cancer;   Carcinoma of the Appendix;   Colorectal Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastric Cancer;   Gastrointestinal Carcinoid Tumor;   Liver Cancer;   Nausea and Vomiting;   Pancreatic Cancer;   Peritoneal Cavity Cancer;   Small Intestine Cancer
    Interventions:   Drug: palonosetron hydrochloride;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster

    Conditions:   Herpes Zoster;   Shingles
    Interventions:   Drug: valacyclovir;   Drug: FV-100;   Drug: FV-100;   Drug: Valacyclovir placebo;   Drug: FV-100 placebo
    Sponsor:   Inhibitex
    Recruiting - verified November 2009

  • Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: protein expression analysis;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified October 2009

  • Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

    Conditions:   Leukemia;   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

    Conditions:   Leukemia;   Neoplasm of Uncertain Malignant Potential;   Unspecified Childhood Solid Tumor, Protocol Specific
    Intervention:   Other: cytology specimen collection procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study of Kidney Tumors in Young Patients

    Conditions:   Kidney Cancer;   Precancerous/Nonmalignant Condition
    Interventions:   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

    Conditions:   Leukemia;   Lymphoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

    Condition:   Sarcoma
    Intervention:   Other: biologic sample preservation procedure
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Study Comparing 3 Dosage Levels of SAM-531 in Outpatients With Mild to Moderate Alzheimer Disease.

    Condition:   Alzheimer Disease
    Intervention:   Drug: Placebo
    Sponsor:   Wyeth
    Recruiting - verified November 2009

  • Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

    Conditions:   Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
    Interventions:   Drug: capecitabine;   Drug: sunitinib malate
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic DMARDs

    Condition:   Rheumatoid Arthritis
    Interventions:   Drug: tocilizumab;   Drug: tocilizumab;   Drug: Nonbiologic DMARDs of investigator's choice
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009

  • A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: bevacizumab;   Drug: docetaxel;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: cyclophosphamide;   Drug: pegfilgrastim
    Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Genentech;   US Oncology Research
    Recruiting - verified October 2009

  • Cisplatin and Etoposide Phosphate With or Without GDC-0449 or Cixutumumab in Treating Patients With Extensive-Stage Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: cixutumumab;   Drug: Hedgehog antagonist GDC-0449;   Drug: cisplatin;   Drug: etoposide phosphate
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy

    Conditions:   Nausea and Vomiting;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: dexamethasone;   Drug: gabapentin;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

    Condition:   Euvolemic Hyponatremia
    Interventions:   Drug: Lixivaptan;   Drug: Placebo
    Sponsors:   CardioKine Inc.;   Cardiokine Biopharma, LLC;   Biogen Idec
    Recruiting - verified November 2009

  • The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633AM1)

    Conditions:   Coronary Artery Bypass;   Myocardial Infarction;   Ventricular Dysfunction, Left;   Stroke;   Cardiopulmonary Bypass
    Interventions:   Drug: Acadesine;   Drug: Normal Saline
    Sponsor:   Schering-Plough
    Recruiting - verified October 2009

  • Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

    Conditions:   Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
    Intervention:   Drug: zoledronic acid
    Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer

    Condition:   Liver Cancer
    Interventions:   Biological: bevacizumab;   Drug: sorafenib tosylate
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Acute Pain Caused by Paclitaxel in Patients With Cancer

    Conditions:   Chemotherapeutic Agent Toxicity;   Neurotoxicity;   Pain;   Unspecified Adult Solid Tumor, Protocol Specific
    Interventions:   Drug: paclitaxel;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Procedure: assessment of therapy complications
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • Anemia Treatment for Advanced NSCLC Patients Receiving Chemotherapy

    Conditions:   Non-small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
    Interventions:   Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
    Sponsor:   Amgen
    Recruiting - verified November 2009

  • Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

    Conditions:   Anemia;   Leukemia;   Myelodysplastic Syndromes
    Interventions:   Biological: epoetin alfa;   Drug: lenalidomide
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease

    Condition:   Alzheimer's Disease
    Interventions:   Drug: Dimebon;   Drug: Placebo;   Drug: Dimebon;   Drug: Placebo
    Sponsors:   Pfizer;   Medivation, Inc.
    Recruiting - verified November 2009

  • Tanezumab In Osteoarthritis Of The Knee (2)

    Conditions:   Arthritis;   Osteoarthritis
    Interventions:   Biological: tanezumab 10 mg;   Biological: tanezumab 5 mg;   Drug: naproxen;   Other: placebo
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine;   Drug: vincristine sulfate;   Radiation: fludeoxyglucose F 18
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified November 2009

  • PF-00299804 As a Single Oral Agent In Untreated Adenocarcinoma Of The Lung In Non-Smokers Or Former Light Smokers

    Condition:   Carcinoma, Non-small Cell
    Intervention:   Drug: PF-00299804
    Sponsor:   Pfizer
    Recruiting - verified November 2009

  • A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis

    Condition:   Arthritis, Rheumatoid
    Interventions:   Drug: CP-690,550;   Drug: CP-690,550;   Drug: Placebo;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting - verified November 2009

    • Menu
    Find Paid Clinical Trials